海王生物(000078) - 2024 Q4 - 年度业绩预告

Financial Performance Expectations - The company expects a net loss of between -1.2 billion and -0.95 billion yuan for the fiscal year 2024, compared to a net loss of -1.689 billion yuan in the previous year[3]. - Revenue is projected to be between 2.8 billion and 3.2 billion yuan, down from 3.641 billion yuan in the previous year[3]. - Basic earnings per share are projected to be a loss of between -0.4561 yuan and -0.3611 yuan, compared to a loss of -0.6423 yuan per share in the previous year[3]. Impairment Provisions - The company anticipates a goodwill impairment provision of approximately 400 million to 570 million yuan due to underperformance of acquired subsidiaries[6]. - An expected provision for accounts receivable impairment is estimated to be between 230 million and 330 million yuan, reflecting prolonged collection periods from hospital clients[6]. - The company is currently undergoing asset impairment testing, with final amounts to be determined by external evaluation and audit[7]. Business Challenges - The decline in main business revenue is attributed to ongoing pressures from national healthcare reforms and centralized procurement policies[5]. Financial Reporting and Disclosure - The financial data presented is preliminary and has not yet been audited by the accounting firm[8]. - The company emphasizes the importance of timely information disclosure and advises investors to be cautious[9]. - The final financial results will be detailed in the 2024 annual report[9].